Member Info for rivaldo

News - all sounds very positive, i.e "a year of unprecedented growth and rapid global expansion": Http://accesso.com/2016/01/accesso-promotes-multiple-executives-to-new-roles-to-accommodate-rapid-company-growth/ "accesso® Promotes Multiple Executives to New Roles to Accommodate Rapid Company Growth January 13, 2016 ORLANDO, Fla. (12-January-2016) – accesso Technology Group plc (AIM: ACSO), the premier technology solutions provider to leisure, entertainment and cultural markets, has promoted four executives following a year of unprecedented growth and rapid global expansion. Andrew Jacobs has been promoted to President, accesso LoQueueSM and Managing Director, Europe; Janel Pisorchik is now President, accesso Passport®; Eric Petrusic has been promoted to Chief Technology Officer; and TJ Christensen is now Executive Vice President, Sales and Marketing. etc"

Good to see a keen pre-open buy of 3k shares today :o)) SOM have been assigned a new patent: Http://www.4-traders.com/SOMERO-ENTERPRISES-INC-4006515/news/Somero-Enterprises-Assigned-Patent-21683082/ "Somero Enterprises : Assigned Patent 01/13/2016 | 07:12am US/Eastern By Targeted News Service ALEXANDRIA, Va., Jan. 13 -- Somero Enterprises, Fort Myers, Florida, has been assigned a patent (9,234,318) developed by two co-inventors for a "roller plow assembly for concrete screeding machine." The co-inventors are Mark A. Pietila, Atlantic Mine, Michigan, and Philip D. Halonen, Calumet, Michigan. The patent application was filed on May 29, 2014 (14/290,027). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=92,34,318.PN.&OS=PN/92,34,318&RS=PN/92,34,318"

New highs soon?

Peel Hunt have reiterated their Buy and 165p target: Http://www.risersandfallers.com/2016/01/12/carclo-plc-retained-as-buy-by-peel-hunt/

Canaccord have heavily increased their forecasts per Hemscott following the trading update. They now go for: - last year (2015) : 14.9p EPS, 4.5p dividend - this year (2016) : 15.9p EPS, 4.8p dividend Very cheap at 138p given that the US construction market is continuing to thrive.

Http://www.investegate.co.uk/regenersis-plc--rgs-/rns/trading-update-and-notice-of-results/201601130700056470L/ - stronger than last year, and in line with expectations of 16p EPS this year (with a 5.36p dividend) - the key Software division firing on all cylinders - several offers received for Aftermarket division

As good a 9-month trading update as you could hope for today: Http://www.investegate.co.uk/energy-assets-gp-plc--eas-/rns/q3-trading-update/201601130700056558L/ Overall and recurring income increasing fast, nicely in line, and a very bulish outlook: "Energy Assets Chief Executive Phil Bellamy-Lee said: "The Group has continued to deliver strong growth in the period which is significantly ahead of the same period in the prior year. The Blyth acquisition represents another positive milestone for Energy Assets as we continue to grow our business, both organically and through acquisition, and extend our product ranges and service offering to a wider multi-utility market sector."

Slater has bought almost another 7m shares and now has 26m. Quite a vote of confidence: Http://www.investegate.co.uk/inspired-energy-plc--inse-/rns/holding-s--in-company/201601121018525852L/ The shares have come from a bit of top-slicing rom the directors, which still leaves them with extremely large holdings and a big incentive to continue INSE's growth.

It seems CDS' baby steps are getting somewhat faster and confidence is increasing.... Http://www.carclodiagnosticsolutions.com/media-centre/press-releases/08-01-2016.aspx "Cambridge (UK), 8 January 2016: Having consolidated and expanded its development team, Carclo Diagnostic Solutions Ltd (“CDS”) will be moving to a new facility in Cambridge in early February 2016 08 Jan 2016 Cambridge (UK), 8 January 2016: Having consolidated and expanded its development team, Carclo Diagnostic Solutions Ltd (“CDS”) will be moving to a new facility in Cambridge in early February 2016. CDS has closed its facility in Daresbury, consolidated and expanded its team and is moving into new premises on the Innovation Park in Cambridge. With biochemists, materials scientists, microfluidics engineers and electronics specialists, CDS’s team now numbers 15. The new facility is equipped with ample office, laboratory and clean room production space....." and: http://www.carclodiagnosticsolutions.com/media-centre/press-releases/08-01-2016a.aspx "Cambridge (UK), 8 January 2016: Carclo Diagnostic Solutions Ltd (“CDS”) will be presenting its latest data via a talk at the forthcoming Point of Care Diagnostics conference & exhibition in Madrid, Spain, 15-16 March 08 Jan 2016 Cambridge (UK), 8 January 2016: Carclo Diagnostic Solutions Ltd (“CDS”) will be presenting its latest data via a talk at the forthcoming Point of Care Diagnostics conference & exhibition in Madrid, Spain, 15-16 March. Organised by Select Biosciences, the event is co-located with Lab on a Chip and Microfluidics conferences and offers an ideal opportunity for CDS to promote its micropoc® technologies and network with industry contacts and potential licensing partners."

FIL are buying more and have increased to above 5%: Http://www.investegate.co.uk/creston-plc--cre-/rns/holding-s--in-company/201601111733505109L/ They've bought almost another 300,000 shares and now have more than 3m.

Great stuff - a €3.4m contract win is huge for a company this size.. The contract sizes are getting much bigger, and it's a vote of confidence from the existing customer too.

on Saturday....this is the first time they've been mentioned by SCSW, so hopefully this means there will be full coverage of LAKE in a forthcoming issue. The valuation does seem to be a ridiculous anomaly on a forward P/E of 6.1 based on 12.4p and then 14.5p EPS per Peel Hunt.

Yet another mention for CHT here - it seems word is finally spreading: http ://www.iii.co.uk/articles/287111/11-small-cap-winners-2016 "Constellation Healthcare Constellation (CHT) provides medical billing services in the US, which is a defensive $37 billion (£25 billion) market and growing at 7%. Complementing this momentum, the group's buy-and-build model works well in such a fragmented market, while its back-office operations are outsourced to India. "This strategy is bearing fruit - we have upgraded forecasts by 44% since IPO in December 2014 - and we believe strong organic growth and cheap valuation leave scope for strong performance in 2016," says Greaves. With a target price of 310p, the bullish broker reckons the shares have 84% upside. This target price represents an enterprise value/cash earnings multiple of 9.6 times, which is still a 31% discount to peers."

Beaufort Securities have summarised as follows this morning: "Venn Life Sciences (VENN.L, 23.0p) - Speculative Buy On Friday, Venn Life Sciences (Venn) released a trading update for the year ended 31st December 2015. The company expects revenue for the full year to be at least twice as much compared to last year (2014: €4.9m). Cash at the end of period stood at €3.4m. In a separate announcement, Venn informed that David Evans, Non-Executive Chairman, resigned from the board, in line with his personal commitment to reduce his number of non-executive chairman roles currently undertaken. Our view: In 2015, Venn experienced a sharp jump in revenue, led by some major contracts won during the period. Moreover, the addition of drug development and service capabilities has enhanced the company’s service offerings. Furthermore, Venn is seeking acquisition opportunities in Central and Eastern Europe in wake of huge opportunities in the region at minimal costs. Venn is well funded with sufficient cash to expand its international coverage. Overall, the company is well placed, with a strong balance sheet and enhanced contract base, to maintain its growth momentum in 2016. Therefore, we maintain our Speculative Buy rating on the stock. "

At some point the market will cotton on to this stock, which is now on a single figure P/E for 2016 with: - a healthy Balance Sheet - solid recurring income - big growth plans, and now an agreed loan facility for further acquisitions Nice to see good coverage in the Times: Http://www.thetimes.co.uk/tto/business/industries/engineering/article4660814.ece "Gama Aviation raises the bar with £10m RBS package at 12:01AM, January 9 2016 Royal Bank of Scotland is backing expansion plans by Gama Aviation, the private jet provider and servicer, with a £10 million funding package. Gama is using some of the cash to buy Aviation Beauport, the Jersey-based aircraft charter firm, subject to approval from competition authorities. Gama will pay £2.6 million in cash and is also issuing a million new shares, giving the deal a total value of £5.3 million. Beauport, established in 1969, is the only premium aircraft provider in the Channel Islands and has a turnover of £6 million. The competition authority in Jersey is expected to give its ruling on the deal by the end of next month. RBS is providing Gama with an £8 million revolving credit facility and an overdraft of £2 million. In Scotland, Gama Aviation runs the air ambulance service, having secured a seven-year contract for £120 million in 2013."

http://uk.advfn.com/stock-market/london/vectura-group-VEC/share-news/Vectura-Group-plc-VR315-US-completes-clinical-stud/69931693 As Dontay posted elsewhere, "AirFluSal Forspiro was previously known as VR315 and is an inhaled combination therapy for asthma and COPD using the GyroHaler dry powder inhaler. GyroHaler is an award winning device which came out of a joint CAR/VEC collaboration with Carclo having manufacturing rights to the device. The device is a generic replacement for one the top selling drugs in the world. It has already been launched on the market in several European countries as well as North Korea and Latin America. This latest win in the USA has been several years in the making and opens up a huge market. Next one up will hopefully be China!" With the success of the Gyrohaler, perhaps CAR will get further contracts from VEC for their other products (or indeed from VEC's many pharmaceutical partners).

Http://www.whatinvestment.co.uk/financial-news/funds/2501321/blackrockand39s-mike-prentis-the-two-uk-smaller-company-technology-stocks-i-have-bought-this-month.thtml "Mike Prentis, the veteran manager of the BlackRock Smaller Companies investment trust, which has returned 77 per cent over the past three years compared to 63 per cent for the average fund in the AIC UK Smaller Companies sector in the same time period, has revealed the two technology stocks in which he has made new investments over the past month. Prentis commented, ‘We added two holdings in the IT sector, NCC Group and Softcat. NCC is a global information assurance specialist providing organisations worldwide with escrow, verification, security consulting and domain services. We took part in a placing to fund the purchase of Fox-IT, based in the Netherlands. Fox is a leading provider of high-end cyber security solutions including advanced threat intelligence."

Http://www.moneyobserver.com/portfolio-ideas/six-speculative-uk-share-tips-2016?utm_source=Newsletter2016-01-08&utm_medium=Email&utm_campaign=ContentPromotion "Constellation Healthcare Technologies (CHT) Constellation Healthcare Technologies is a US-based provider of billing services to doctors there. It floated in London a year ago at 135p, and the shares have done well. Acquisitions are a key part of the strategy, but better-than-expected organic growth means full-year cash profit will be at the top end of market expectations. There's plenty of opportunity to grow in this highly fragmented market worth $37 billion (£24 billion) annually. Analysts predict annual profit growth averaging around 20 per cent over the next two years for Constellation."

Excellent trading statement today, with doubled sales of likely €10m+ and plenty of cash (€3.4m) going forward. Looking very strong now.

Excellent earnings-enhancing acquisition today. I've been buying a few more here. Latest forecasts from Cantors, who have a 400p target, are now out - they show: last year (2015) : 22.56p EPS, 2.3p divi this year (2016) : 27.86p EPS, 2.8p divi I'd imagine those forecasts will now be lifted for today's acquisition. Assuming the year end trading statement is in line at worst - and the interims outlook was very confident - then there's scope for a 50%+ uplift from here imo, and possibly a lot more.